Bleichroeder LP Buys Shares of 173,900 Alpha Cognition, Inc. (NASDAQ:ACOG)

Bleichroeder LP bought a new stake in shares of Alpha Cognition, Inc. (NASDAQ:ACOG - Free Report) during the fourth quarter, according to the company in its most recent filing with the SEC. The institutional investor bought 173,900 shares of the company's stock, valued at approximately $1,024,000. Bleichroeder LP owned about 1.09% of Alpha Cognition as of its most recent filing with the SEC.

Other hedge funds also recently bought and sold shares of the company. Alyeska Investment Group L.P. acquired a new position in shares of Alpha Cognition in the fourth quarter valued at approximately $2,356,000. Manatuck Hill Partners LLC acquired a new position in Alpha Cognition in the 4th quarter valued at $395,000. Tudor Investment Corp ET AL purchased a new position in shares of Alpha Cognition during the 4th quarter worth $412,000. Boothbay Fund Management LLC acquired a new stake in shares of Alpha Cognition during the fourth quarter worth $1,284,000. Finally, Solas Capital Management LLC acquired a new position in Alpha Cognition in the fourth quarter valued at $8,096,000.

Wall Street Analyst Weigh In

A number of research firms have recently commented on ACOG. Raymond James upgraded Alpha Cognition to a "moderate buy" rating in a report on Tuesday, March 25th. HC Wainwright reaffirmed a "buy" rating and set a $20.00 price target on shares of Alpha Cognition in a research note on Monday, March 31st.

Alpha Cognition Trading Up 7.6 %

NASDAQ ACOG traded up $0.53 during mid-day trading on Wednesday, reaching $7.49. 229,364 shares of the company's stock traded hands, compared to its average volume of 82,552. Alpha Cognition, Inc. has a 1-year low of $3.75 and a 1-year high of $8.61. The firm's fifty day simple moving average is $5.18. The stock has a market capitalization of $119.99 million, a P/E ratio of -2.93 and a beta of 2.48.

Alpha Cognition (NASDAQ:ACOG - Get Free Report) last released its quarterly earnings results on Monday, March 31st. The company reported ($0.51) earnings per share for the quarter, missing analysts' consensus estimates of ($0.48) by ($0.03).

About Alpha Cognition

Alpha Cognition, Inc is a clinical stage biopharmaceutical company that develops treatments for underserved neurodegenerative diseases such as Alzheimer's Dementia and Amyotrophic Lateral Sclerosis. The company was founded in 2000 and is headquartered in Vancouver, Canada.